Modelling of Parkinson's disease in mice

The Lancet Neurology

Volumn 10, Issue 12, 2011, Pages 1108-1118

  Chesselet, Marie Françoise ^a   Richter, Franziska ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ALPHA SYNUCLEIN; BUTYRIC ACID DERIVATIVE; DAVUNETIDE; DIMEBON; DOPAMINE; EICOSANOYL 5 HYDROXYTRYPTAMIDE; LEVODOPA; MEVINOLIN; NEUROPROTECTIVE AGENT; SODIUM 4 PHENYLBUTYRIC ACID; TRYPTAMIDE; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANXIETY; AUTONOMIC DYSFUNCTION; BRAIN MITOCHONDRION; BRAIN NERVE CELL; CELL INCLUSION; COGNITIVE DEFECT; CORPUS STRIATUM; DISEASE COURSE; DOPAMINE BRAIN LEVEL; DOPAMINERGIC NERVE CELL; EXPERIMENTAL MOUSE; GASTROINTESTINAL DISEASE; GENE MUTATION; GENETIC MODEL; HEREDITY; HUMAN; IMMUNIZATION; MOUSE; NERVE CELL NECROSIS; NEUROPATHOLOGY; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN AGGREGATION; REVIEW; SMELLING DISORDER;

ANIMALS; DISEASE MODELS, ANIMAL; LEVODOPA; MICE; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE;

EID: 81255210997     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(11)70227-7     Document Type: Review

References (100)

1. Elbaz A, Bower JH, Maraganore DM, et al. Risk tables for parkinsonism and Parkinson's disease. J Clin Epidemiol 2002, 55:25-31.
2. Meissner WG, Frasier M, Gasser T, et al. Priorities in Parkinson's disease research. Nat Rev Drug Discov 2011, 10:377-393.
3. DeLong MR, Juncos JL Parkinson's disease and other extrapyramidal movement disorders. Harrison's principles of internal medicine 2008, 2549-2559. McGraw-Hill, New York, NY. 17 edn.
4. Olanow CW, Stern MB, Sethi K The scientific and clinical basis for the treatment of Parkinson disease. Neurology 2009, 72(suppl 4):S1-136.
5. Shulman JM, De Jager PL, Feany MB Parkinson's disease: genetics and pathogenesis. Annu Rev Pathol 2011, 6:193-222.
6. Magen I, Chesselet MF Genetic mouse models of Parkinson's disease: the state of the art. Prog Brain Res 2010, 184:53-87.
7. Beal MF Parkinson's disease: a model dilemma. Nature 2010, 466:S8-10.
8. Brooks DJ Imaging dopamine transporters in Parkinson's disease. Biomark Med 2011, 4:651-660.
9. Stoessl AJ Neuroimaging in Parkinson's disease. Neurotherapeutics 2011, 8:72-81.
10. Cannon JR, Greenamyre JT Neurotoxic in vivo models of Parkinson's disease: recent advances. Prog Brain Res 2011, 184:17-33.
11. Fox SH, Brotchie JM The MPTP-lesioned non-human primate models of Parkinson's disease: past, present, and future. Prog Brain Res 2011, 184:133-157.
12. Langston JW MPTP neurotoxicity: an overview and characterization of phases of toxicity. Life Sci 1985, 36:201-206.
13. Wang A, Costello S, Cockburn M, Zhang X, Bronstein J, Ritz B Parkinson's disease risk from ambient exposure to pesticides. Eur J Epidemiol 2011, 26:547-555.
14. Lohle M, Reichmann H Clinical neuroprotection in Parkinson's disease-still waiting for the breakthrough. J Neurol Sci 2010, 289:104-114.
15. Cookson MR The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease. Nat Rev Neurosci 2010, 11:791-797.
16. Spillantini MG, Goedert M The alpha-synucleinopathies: Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy. Ann N Y Acad Sci 2000, 920:16-27.
17. Hardy J Genetic analysis of pathways to Parkinson disease. Neuron 2010, 68:201-206.
18. Hwang DY, Fleming SM, Ardayfio P, et al. 3,4-dihydroxyphenylalanine reverses the motor deficits in Pitx3-deficient aphakia mice: behavioral characterization of a novel genetic model of Parkinson's disease. J Neurosci 2005, 25:2132-2137.
19. Good CH, Hoffman AF, Hoffer BJ, et al. Impaired nigrostriatal function precedes behavioral deficits in a genetic mitochondrial model of Parkinson's disease. FASEB J 2011, 25:1333-1344.
20. Galter D, Pernold K, Yoshitake T, et al. MitoPark mice mirror the slow progression of key symptoms and L-DOPA response in Parkinson's disease. Genes Brain Behav 2010, 9:173-181.
21. Choi WS, Palmiter RD, Xia Z Loss of mitochondrial complex I activity potentiates dopamine neuron death induced by microtubule dysfunction in a Parkinson's disease model. J Cell Biol 2011, 192:873-882.
22. Taylor TN, Caudle WM, Miller GW VMAT2-deficient mice display nigral and extranigral pathology and motor and nonmotor symptoms of Parkinson's disease. Parkinsons Dis 2011, 2011:124165.
23. Taylor TN, Caudle WM, Shepherd KR, et al. Nonmotor symptoms of Parkinson's disease revealed in an animal model with reduced monoamine storage capacity. J Neurosci 2009, 29:8103-8113.
24. Masliah E, Rockenstein E, Veinbergs I, et al. Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science 2000, 287:1265-1269.
25. Hashimoto M, Rockenstein E, Masliah E Transgenic models of alpha-synuclein pathology: past, present, and future. Ann N Y Acad Sci 2003, 991:171-188.
26. Clark J, Clore EL, Zheng K, Adame A, Masliah E, Simon DK Oral N-acetyl-cysteine attenuates loss of dopaminergic terminals in alpha-synuclein overexpressing mice. PLoS One 2010, 5:e12333.
27. Masliah E, Rockenstein E, Mante M, et al. Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease. PLoS One 2011, 6:e19338.
28. Koob AO, Ubhi K, Paulsson JF, et al. Lovastatin ameliorates alpha-synuclein accumulation and oxidation in transgenic mouse models of alpha-synucleinopathies. Exp Neurol 2010, 221:267-274.
29. Rockenstein E, Mallory M, Hashimoto M, et al. Differential neuropathological alterations in transgenic mice expressing alpha-synuclein from the platelet-derived growth factor and Thy-1 promoters. J Neurosci Res 2002, 68:568-578.
30. Fernagut PO, Hutson CB, Fleming SM, et al. Behavioral and histopathological consequences of paraquat intoxication in mice: effects of alpha-synuclein over-expression. Synapse 2007, 61:991-1001.
31. Lam HA, Wu N, Cely I, et al. Elevated tonic extracellular dopamine concentration and altered dopamine modulation of synaptic activity precede dopamine loss in the striatum of mice overexpressing human alpha-synuclein. J Neurosci Res 2011, 89:1091-1102.
32. Fleming SM, Tetreault NA, Mulligan CK, Hutson CB, Masliah E, Chesselet MF Olfactory deficits in mice overexpressing human wildtype alpha-synuclein. Eur J Neurosci 2008, 28:247-256.
33. Kudo T, Loh DH, Truong D, Wu Y, Colwell CS Circadian dysfunction in a mouse model of Parkinson's disease. Exp Neurol 2011, 232:66-75.
34. Fleming SM, Salcedo J, Fernagut PO, et al. Early and progressive sensorimotor anomalies in mice overexpressing wild-type human alpha-synuclein. J Neurosci 2004, 24:9434-9440.
35. Wu N, Joshi PR, Cepeda C, Masliah E, Levine MS Alpha-synuclein overexpression in mice alters synaptic communication in the corticostriatal pathway. J Neurosci Res 2010, 88:1764-1776.
36. Fleming SM, Mulligan CK, Richter F, et al. A pilot trial of the microtubule-interacting peptide (NAP) in mice overexpressing alpha-synuclein shows improvement in motor function and reduction of alpha-synuclein inclusions. Mol Cell Neurosci 2011, 46:597-606.
37. Nuber S, Petrasch-Parwez E, Winner B, et al. Neurodegeneration and motor dysfunction in a conditional model of Parkinson's disease. J Neurosci 2008, 28:2471-2484.
38. Lim Y, Kehm VM, Li C, Trojanowski JQ, Lee VM Forebrain overexpression of alpha-synuclein leads to early postnatal hippocampal neuron loss and synaptic disruption. Exp Neurol 2010, 221:86-97.
39. Lim Y, Kehm VM, Lee EB, et al. α-Syn suppression reverses synaptic and memory defects in a mouse model of dementia with Lewy bodies. J Neurosci 2011, 31:10076-10087.
40. van der Putten H, Wiederhold KH, Probst A, et al. Neuropathology in mice expressing human alpha-synuclein. J Neurosci 2000, 20:6021-6029.
41. Neumann M, Kahle PJ, Giasson BI, et al. Misfolded proteinase K-resistant hyperphosphorylated alpha-synuclein in aged transgenic mice with locomotor deterioration and in human alpha-synucleinopathies. J Clin Invest 2002, 110:1429-1439.
42. Schell H, Hasegawa T, Neumann M, Kahle PJ Nuclear and neuritic distribution of serine-129 phosphorylated alpha-synuclein in transgenic mice. Neuroscience 2009, 160:796-804.
43. Freichel C, Neumann M, Ballard T, et al. Age-dependent cognitive decline and amygdala pathology in alpha-synuclein transgenic mice. Neurobiol Aging 2007, 28:1421-1435.
44. Ono K, Ikemoto M, Kawarabayashi T, et al. A chemical chaperone, sodium 4-phenylbutyric acid, attenuates the pathogenic potency in human alpha-synuclein A30P + A53T transgenic mice. Parkinsonism Relat Disord 2009, 15:649-654.
45. Lee MK, Stirling W, Xu Y, et al. Human alpha-synuclein-harboring familial Parkinson's disease-linked Ala-53 → Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice. Proc Natl Acad Sci USA 2002, 99:8968-8973.
46. Unger EL, Eve DJ, Perez XA, et al. Locomotor hyperactivity and alterations in dopamine neurotransmission are associated with overexpression of A53T mutant human alpha-synuclein in mice. Neurobiol Dis 2006, 21:431-443.
47. Giasson BI, Duda JE, Quinn SM, Zhang B, Trojanowski JQ, Lee VM Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. Neuron 2002, 34:521-533.
48. Martin LJ, Pan Y, Price AC, et al. Parkinson's disease alpha-synuclein transgenic mice develop neuronal mitochondrial degeneration and cell death. J Neurosci 2006, 26:41-50.
49. Sotiriou E, Vassilatis DK, Vila M, Stefanis L Selective noradrenergic vulnerability in alpha-synuclein transgenic mice. Neurobiol Aging 2010, 31:2103-2114.
50. Kurz A, Double KL, Lastres-Becker I, et al. A53T-alpha-synuclein overexpression impairs dopamine signaling and striatal synaptic plasticity in old mice. PLoS One 2010, 5:e11464.
51. Gispert S, Del Turco D, Garrett L, et al. Transgenic mice expressing mutant A53T human alpha-synuclein show neuronal dysfunction in the absence of aggregate formation. Mol Cell Neurosci 2003, 24:419-429.
52. Yavich L, Oksman M, Tanila H, et al. Locomotor activity and evoked dopamine release are reduced in mice overexpressing A30P-mutated human alpha-synuclein. Neurobiol Dis 2005, 20:303-313.
53. Richfield EK, Thiruchelvam MJ, Cory-Slechta DA, et al. Behavioral and neurochemical effects of wild-type and mutated human alpha-synuclein in transgenic mice. Exp Neurol 2002, 175:35-48.
54. Thiruchelvam MJ, Powers JM, Cory-Slechta DA, Richfield EK Risk factors for dopaminergic neuron loss in human alpha-synuclein transgenic mice. Eur J Neurosci 2004, 19:845-854.
55. Kuo YM, Li Z, Jiao Y, et al. Extensive enteric nervous system abnormalities in mice transgenic for artificial chromosomes containing Parkinson disease-associated alpha-synuclein gene mutations precede central nervous system changes. Hum Mol Genet 2010, 19:1633-1650.
56. Zhou W, Milder JB, Freed CR Transgenic mice overexpressing tyrosine-to-cysteine mutant human alpha-synuclein: a progressive neurodegenerative model of diffuse Lewy body disease. J Biol Chem 2008, 283:9863-9870.
57. Tofaris GK, Garcia Reitbock P, Humby T, et al. Pathological changes in dopaminergic nerve cells of the substantia nigra and olfactory bulb in mice transgenic for truncated human alpha-synuclein(1-120): implications for Lewy body disorders. J Neurosci 2006, 26:3942-3950.
58. Shelkovnikova TA, Ustyugov AA, Millership S, et al. Dimebon does not ameliorate pathological changes caused by expression of truncated (1-120) human alpha-synuclein in dopaminergic neurons of transgenic mice. Neurodegener Dis 2011, 8:430-437.
59. Wakamatsu M, Ishii A, Iwata S, et al. Selective loss of nigral dopamine neurons induced by overexpression of truncated human alpha-synuclein in mice. Neurobiol Aging 2008, 29:574-585.
60. Zhu XR, Maskri L, Herold C, et al. Non-motor behavioural impairments in parkin-deficient mice. Eur J Neurosci 2007, 26:1902-1911.
61. Goldberg MS, Fleming SM, Palacino JJ, et al. Parkin-deficient mice exhibit nigrostriatal deficits but not loss of dopaminergic neurons. J Biol Chem 2003, 278:43628-43635.
62. Shin JH, Ko HS, Kang H, et al. PARIS (ZNF746) repression of PGC-1alpha contributes to neurodegeneration in Parkinson's disease. Cell 2011, 144:689-702.
63. Lu XH, Fleming SM, Meurers B, et al. Bacterial artificial chromosome transgenic mice expressing a truncated mutant parkin exhibit age-dependent hypokinetic motor deficits, dopaminergic neuron degeneration, and accumulation of proteinase K-resistant alpha-synuclein. J Neurosci 2009, 29:1962-1976.
64. Pham TT, Giesert F, Rothig A, et al. DJ-1-deficient mice show less TH-positive neurons in the ventral tegmental area and exhibit non-motoric behavioural impairments. Genes Brain Behav 2010, 9:305-317.
65. Chen L, Cagniard B, Mathews T, et al. Age-dependent motor deficits and dopaminergic dysfunction in DJ-1 null mice. J Biol Chem 2005, 280:21418-21426.
66. Goldberg MS, Pisani A, Haburcak M, et al. Nigrostriatal dopaminergic deficits and hypokinesia caused by inactivation of the familial Parkinsonism-linked gene DJ-1. Neuron 2005, 45:489-496.
67. Gispert S, Ricciardi F, Kurz A, et al. Parkinson phenotype in aged PINK1-deficient mice is accompanied by progressive mitochondrial dysfunction in absence of neurodegeneration. PLoS One 2009, 4:e5777.
68. Akundi RS, Huang Z, Eason J, et al. Increased mitochondrial calcium sensitivity and abnormal expression of innate immunity genes precede dopaminergic defects in Pink1-deficient mice. PLoS One 2011, 6:e16038.
69. Kitada T, Tong Y, Gautier CA, Shen J Absence of nigral degeneration in aged parkin/DJ-1/PINK1 triple knockout mice. J Neurochem 2009, 111:696-702.
70. Li Y, Liu W, Oo TF, et al. Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson's disease. Nat Neurosci 2009, 12:826-828.
71. Tong Y, Pisani A, Martella G, et al. R1441C mutation in LRRK2 impairs dopaminergic neurotransmission in mice. Proc Natl Acad Sci USA 2009, 106:14622-14627.
72. Li X, Patel JC, Wang J, et al. Enhanced striatal dopamine transmission and motor performance with LRRK2 overexpression in mice is eliminated by familial Parkinson's disease mutation G2019S. J Neurosci 2010, 30:1788-1797.
73. Ramonet D, Daher JP, Lin BM, et al. Dopaminergic neuronal loss, reduced neurite complexity and autophagic abnormalities in transgenic mice expressing G2019S mutant LRRK2. PLoS One 2011, 6:e18568.
74. Dawson TM, Ko HS, Dawson VL Genetic animal models of Parkinson's disease. Neuron 2010, 66:646-661.
75. Harvey BK, Richie CT, Hoffer BJ, Airavaara M Transgenic animal models of neurodegeneration based on human genetic studies. J Neural Transm 2011, 118:27-45.
76. Oyama G, Yoshimi K, Natori S, et al. Impaired in vivo dopamine release in parkin knockout mice. Brain Res 2010, 1352:214-222.
77. Hawkes CH, Del Tredici K, Braak H A timeline for Parkinson's disease. Parkinsonism Relat Disord 2010, 16:79-84.
78. Kahle PJ alpha-Synucleinopathy models and human neuropathology: similarities and differences. Acta Neuropathol 2008, 115:87-95.
79. Lee KW, Chen W, Junn E, et al. Enhanced phosphatase activity attenuates alpha-synucleinopathy in a mouse model. J Neurosci 2011, 31:6963-6971.
80. Zhou J, Broe M, Huang Y, et al. Changes in the solubility and phosphorylation of alpha-synuclein over the course of Parkinson's disease. Acta Neuropathol 2011, 121:695-704.
81. Schon EA, Przedborski S Mitochondria: the next (neurode)generation. Neuron 2011, 70:1033-1053.
82. Zheng B, Liao Z, Locascio JJ, et al. PGC-1alpha, a potential therapeutic target for early intervention in Parkinson's disease. Sci Transl Med 2010, 2:52ra73.
83. Guo M What have we learned from Drosophila models of Parkinson's disease?. Prog Brain Res 2010, 184:3-16.
84. Vives-Bauza C, Zhou C, Huang Y, et al. PINK1-dependent recruitment of Parkin to mitochondria in mitophagy. Proc Natl Acad Sci USA 2010, 107:378-383.
85. Nakamura K, Nemani VM, Azarbal F, et al. Direct membrane association drives mitochondrial fission by the Parkinson disease-associated protein alpha-synuclein. J Biol Chem 2011, 286:20710-20726.
86. Palacino JJ, Sagi D, Goldberg MS, et al. Mitochondrial dysfunction and oxidative damage in parkin-deficient mice. J Biol Chem 2004, 279:18614-18622.
87. Gautier CA, Kitada T, Shen J Loss of PINK1 causes mitochondrial functional defects and increased sensitivity to oxidative stress. Proc Natl Acad Sci USA 2008, 105:11364-11369.
88. Krebiehl G, Ruckerbauer S, Burbulla LF, et al. Reduced basal autophagy and impaired mitochondrial dynamics due to loss of Parkinson's disease-associated protein DJ-1. PLoS One 2010, 5:e9367.
89. Hao LY, Giasson BI, Bonini NM DJ-1 is critical for mitochondrial function and rescues PINK1 loss of function. Proc Natl Acad Sci USA 2010, 107:9747-9752.
90. Stichel CC, Zhu XR, Bader V, Linnartz B, Schmidt S, Lubbert H Mono- and double-mutant mouse models of Parkinson's disease display severe mitochondrial damage. Hum Mol Genet 2007, 16:2377-2393.
91. Taylor TN, Greene JG, Miller GW Behavioral phenotyping of mouse models of Parkinson's disease. Behav Brain Res 2010, 211:1-10.
92. Chaudhuri KR, Odin P The challenge of non-motor symptoms in Parkinson's disease. Prog Brain Res 2010, 184:325-341.
93. Valappil RA, Black JE, Broderick MJ, et al. Exploring the electrocardiogram as a potential tool to screen for premotor Parkinson's disease. Mov Disord 2010, 25:2296-2303.
94. Wang L, Fleming SM, Chesselet MF, Tache Y Abnormal colonic motility in mice overexpressing human wild-type alpha-synuclein. Neuroreport 2008, 19:873-876.
95. Mirelman A, Gurevich T, Giladi N, Bar-Shira A, Orr-Urtreger A, Hausdorff JM Gait alterations in healthy carriers of the LRRK2 G2019S mutation. Ann Neurol 2011, 69:193-197.
96. Sossi V, de la Fuente-Fernandez R, Nandhagopal R, et al. Dopamine turnover increases in asymptomatic LRRK2 mutations carriers. Mov Disord 2010, 25:2717-2723.
97. Graham DR, Sidhu A Mice expressing the A53T mutant form of human alpha-synuclein exhibit hyperactivity and reduced anxiety-like behavior. J Neurosci Res 2010, 88:1777-1783.
98. Lee SJ, Lim HS, Masliah E, Lee HJ Protein aggregate spreading in neurodegenerative diseases: problems and perspectives. Neurosci Res 2011, 70:339-348.
99. Mata IF, Shi M, Agarwal P, et al. SNCA variant associated with Parkinson disease and plasma alpha-synuclein level. Arch Neurol 2010, 67:1350-1356.
100. Zecca L, Zucca FA, Albertini A, Rizzio E, Fariello RG A proposed dual role of neuromelanin in the pathogenesis of Parkinson's disease. Neurology 2006, 67(suppl 2):S8-11.